AYTU.US is now known as Visus Therapeutics Inc. (VISU). Here's what affects its stock price: Clinical Trial Results: Positive or negative data from Visus's ophthalmic product trials significantly impacts investor confidence and stock valuation.

Regulatory Approvals: FDA approvals or rejections for Visus's drug candidates are major catalysts influencing the stock price.

Market Competition: The presence and success of competing products in the ophthalmology market affect Visus's potential market share and revenue.

Partnerships and Collaborations: Agreements with other pharmaceutical companies or research institutions can boost Visus's prospects and share value.

Financial Performance: Revenue, earnings, cash flow, and debt levels reported in Visus's financial statements influence investor sentiment.

Overall Market Conditions: General economic trends, investor sentiment, and market volatility can impact the prices of small-cap biotech stocks like Visus.

Analyst Ratings and Price Targets: Recommendations from investment analysts and their projected stock prices can affect trading activity.

News and Media Coverage: Positive or negative news articles, press releases, and social media discussions can influence investor perception.

Management Team and Strategy: The experience and strategic decisions of Visus's leadership team play a role in the company's performance and stock price.

Intellectual Property: The strength and protection of Visus's patents and other intellectual property are important for its long-term value.